Mycenax Biotech (4726) — Cash Flow Quality Index
Mycenax Biotech (4726) has a Cash Flow Quality Index of 3.23x as of March 2022. Operating cash flow of NT$59.07 Million exceeds net income of NT$18.31 Million, indicating high earnings quality where cash backs reported profits. Explore how efficiently does Mycenax Biotech generate cash to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Mycenax Biotech Cash Flow Quality Index (2020–2020)
Historical Cash Flow Quality Index for Mycenax Biotech across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 4726 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Mycenax Biotech (2020–2020)
Year-by-year earnings quality comparison for Mycenax Biotech. For live market cap and the full company financial profile, see Mycenax Biotech (4726) market capitalisation.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2020 | 5.63x | NT$174.17 Million | NT$30.95 Million | — |